Skip to main content

Table 2 Patient characteristics

From: Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

  Included patients (n=102)
Age, years* 69 (24–91)
Male sex, n (%) 79 (77.5)
APACHE II** 12.4 ± 5.68
Clinical status, n (%):  
- Severe sepsis 48 (47.1)
- Shock 8 (7.8)
Intensive Care Unit admission, n (%) 24 (23.5)
Type of infection, n (%)  
- Pneumonia 24 (23.5)
- Acute bronchitis 23 (22.5)
- Urinary tract infection 15 (14.7)
- Skin and soft tissue infection and surgical site infection 15 (14.7)
- Bacteremia 5 (4.9)
- Others 20 (19.6)
Type of CMS treatment, n (%)  
- Empirical 3 (2.9)
- Directed: 99 (97.1)
- Pseudomonas aeruginosa 89 (89.9)
- Acinetobacter baumannii 9 (9.1)
- Klebsiella pneumoniae 1 (1)
1CMS daily dose (millions IU)** 5.21 ± 2.24
1CMS total dose, (MU)** 100.54 ± 92.8
1CMS duration, days** 19.57 ± 15.4
2GFR at baseline (ml/min/1.73 m2)* 127.9 (22.3-560)
Patients with 3CKD at baseline, n (%) 23 (22.5)
4Cmin (mg/mL)* 1.06 (0.11-5.99)
5Cmax (mg/mL)* 1.11 (0.15-6.62)
Patients with nephrotoxicity at day 7, n (%) 26 (25.5)
- R (Risk) 16 (61.5)
- I (Injury) 8 (30.7)
- F (Failure) 2 (7.6)
Patients with nephrotoxicity at the end of treatment, n (%) 50 (49)
- R (Risk) 13 (26)
- I (Injury) 23(46)
- F (Failure) 14 (28)
Clinical response, n (%) 79 (77.5)
  1. Data are n (%) except where indicated.
  2. * Median (interquartile range).
  3. ** Mean ± SD.
  4. 1CMS:colistinmethanesulfonate sodium. 2GFR: Glomerular filtration rate. 3CKD: chronic kidney disease. 4Cmin: colistin trough plasma concentrations at steady state. 5Cmax: colistin maximum plasma concentrations at steady state.